193 related articles for article (PubMed ID: 33416947)
21. Spectral Analysis Based on Hemodynamic Habitat Imaging Predicts Isocitrate Dehydrogenase Status and Prognosis in High-Grade Glioma.
Qiao J; Wu H; Liu J; Kang H; Wang S; Fang J; Zhang J; Zhang W
World Neurosurg; 2023 Jul; 175():e520-e530. PubMed ID: 37028478
[TBL] [Abstract][Full Text] [Related]
22.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
23. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
[TBL] [Abstract][Full Text] [Related]
24. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
25. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
26. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
[TBL] [Abstract][Full Text] [Related]
27. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
28. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
30. Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
Huo X; Wang Y; Ma S; Zhu S; Wang K; Ji Q; Chen F; Wang L; Wu Z; Li W
Medicine (Baltimore); 2023 Dec; 102(51):e36581. PubMed ID: 38134061
[TBL] [Abstract][Full Text] [Related]
31. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
Najem H; Khasraw M; Heimberger AB
Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
[TBL] [Abstract][Full Text] [Related]
32. Machine learning-based quantitative texture analysis of conventional MRI combined with ADC maps for assessment of IDH1 mutation in high-grade gliomas.
Alis D; Bagcilar O; Senli YD; Yergin M; Isler C; Kocer N; Islak C; Kizilkilic O
Jpn J Radiol; 2020 Feb; 38(2):135-143. PubMed ID: 31741126
[TBL] [Abstract][Full Text] [Related]
33. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
34. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
35. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
36. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
[TBL] [Abstract][Full Text] [Related]
37. Mathematical modeling of PDGF-driven glioma reveals the dynamics of immune cells infiltrating into tumors.
Niu B; Zeng X; Phan TA; Szulzewsky F; Holte S; Holland EC; Tian JP
Neoplasia; 2020 Sep; 22(9):323-332. PubMed ID: 32585427
[TBL] [Abstract][Full Text] [Related]
38. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
39. Tumor Purity as an Underlying Key Factor in Glioma.
Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
[No Abstract] [Full Text] [Related]
40. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]